Jennifer Doudna and Jonathan Weissman. BARBARA RIES for UCSF
GSK's Barron joins hands with Doudna, Weissman to deploy CRISPR tech in drug discovery
When Hal Barron unveiled his grand plan to turn GlaxoSmithKline’s R&D group around, he championed genetics as one of two key focuses for the UK pharma giant, announcing a discovery deal with 23andme and pledging to focus more on CRISPR tech as well as machine learning. A year later, the R&D chief is building on that promise as he seals a new pact with two prominent CRISPR researchers in his neighborhood in San Francisco.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
